Tanespimycin (17-allylamino-17-demethoxygeldanamycin, 17-AAG) is a synthetic analogue of geldanamycin, an antibiotic first purified in 1970 from Streptomyces hygroscopicus. Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer. Tanespimycin was being under development by Kosan Biosciences. It was in phase 3 clinical development with bortezomib for the treatment of multiple myeloma (MM). However, in 2010 the company halted development of tanespimycin, during late-stage clinical trials as a potential treatment for multiple myeloma. While no definitive explanation was given, it has been suggested that Bristol-Myers Squibb halted development over concerns of the financial feasibility of tanespimycin development given the 2014 expiry of the patent on this compound, and the relative expense of manufacture.

Fispemifene acts via estrogen receptors and has tissue-selective estrogenic and/or antiestrogenic effects – it has antagonist activity in breast tissue and acts as an estrogen agonist in bone. Due to its low estrogenicity in male rats, it might also be applicable for men. Fispemifene exhibits both antiestrogenic and anti-inflammatory action in the prostate. It could be considered as a new therapeutic option in the treatment and prevention of prostatic inflammation. Fispemifene had been in phase II clinical trials for the oral treatment of hypogonadism.

FLUCETOREX is a substituted amphetamine with anorectic activity.

FLUALAMIDE is an antiemetic agent.

Plafibride is an acyl derivative of morpholinomethylurea (MMU) with clofibric acid. Plafibride is hypolipemic, platelet aggregation inhibiting agent. Plafibride did not act on the arachidonic acid metabolism. Plafibride inhibited the activity of 3',5'-cyclic AMP-phosphodiesterase, which is one of the principal mechanisms of inhibition of platelet aggregation. In the rat, plafibride inhibited significantly the spontaneously formed circulating platelet aggregates. In vitro plafibride appeared as an effective antiaggregant agent although less powerful than morpholinomethylurea, one of its presumed metabolites. The most evident secondary effects of plafibride were: a certain sedation, as a light tranquilizing agent, a hypothermic effect when it was administered at high doses, a certain beta-blocking and antiarrhythmic activity probably due to its local anesthetic action. All the side effects appeared at high doses, much higher than the therapeutic ones.

FK-614, a benzimidazole derivative without a thiazolidinedione structure, is a selective peroxisome proliferator-activated receptor gamma agonist. It is a diabetes drug candidate that found implication in pain, including post-herpetic neuralgia.

Tenocyclidine (TCP) is a dissociative anesthetic drug with psychostimulant and hallucinogenic effects. This drug shows a broad spectrum of pharmacological activity including antidotal effect in organophosphorus compounds poisoning, radioprotective and anticancer effects. It was studied that the antidotal potency could protect acetylcholinesterase (AChE) in the case of organophosphate poisoning. However, the controversial role of TCP in brain protection should be studied further. Tenocyclidine has a high affinity for the N-methyl-D-aspartate (NMDA) receptors. This property allows using of TCP binding (association rate) as a marker of channel opening and thereby permitting measurement of NMDA receptor activation and ligand binding under identical conditions.